Overview

• AbbVie increased its 2025 adjusted earnings per share (EPS) forecast to $12.09–$12.29, up from its prior range of $11.99–$12.19.
• First-quarter revenue grew 8% year-over-year to $13.34 billion, surpassing analyst estimates of $12.92 billion.
• Sales of Skyrizi and Rinvoq surged to $3.43 billion and $1.72 billion, respectively, both exceeding Wall Street expectations.
• Global sales of Humira fell by 50% to $1.12 billion, missing projections of $1.32 billion, as biosimilar competition intensified.
• AbbVie acknowledged that its updated forecast does not account for potential U.S. pharmaceutical tariffs, which remain an unresolved risk.